echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Vagus nerve stimulation-a potential new treatment to help stroke patients recover

    Vagus nerve stimulation-a potential new treatment to help stroke patients recover

    • Last Update: 2021-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This article comes from the NEJM Journal Watch A Potential New Treatment to Assist Stroke Recovery.
    A Potential New Treatment to Assist Stroke Recovery.
    A review of potential new treatments that can help stroke patients.
    Author: Seemant Chaturvedi, MD.
    A false stimulation control study on vagus nerve stimulation was obtained on safety And preliminary results of efficacy
    .

    Among survivors of ischemic stroke, it is reported that about 60% still have some degree of upper limb weakness at 6 months after the stroke
    .

    Physicians will provide these patients with conventional physical and occupational therapy, and a new therapy combines vagus nerve stimulation (VNS) with the above treatments
    .

    In rodent models, VNS improves limb function after stroke.
    The mechanism may be the regulation of neurotransmitters in the motor cortex
    .

    In order to test VNS in humans, the researchers conducted a false stimulus-controlled study on VNS in patients with a history of stroke and symptoms involving the upper limbs
    .

    This research was funded by the manufacturer
    .

    Patients in the VNS group received stimulation and treatment 3 times a week for 6 weeks
    .

    The control group received the same treatment plan and fake stimulation
    .

    All patients received instructions on home exercise programs
    .

    The primary end point was the Fugl-Meyer Assessment Scale-Upper Limb Function (FMA-UE) score on the 2nd day after the last face-to-face treatment
    .

    The secondary endpoint is a "clinically significant improvement" at 90 days, which is defined as an improvement in FMA-UE score ≥ 6 points
    .

    Among the 106 patients who completed the study (mean age 60 years; 65% were men), the FMA-UE scale score of the VNS group improved by 5.
    0 points, while the sham stimulation group improved by 2.
    4 points.
    There was a significant difference between the two groups
    .

    At the 90th day, 47% of the patients in the VNS group achieved a clinically significant improvement, compared with 24% in the control group
    .
    There was also a significant difference between the two groups .

    One patient in the VNS group developed temporary vocal cord paralysis
    .

    Comment This innovative trial tests a potential new therapy for improving the recovery of stroke patients
    .

    This study initially showed safety and efficacy, but the sample size was too small to change clinical practice
    .

    We need to carry out larger trials to confirm clinically significant effects and evaluate the subgroups that benefit the most
    .

    Dawson J et al.
    Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): A randomised, blinded, pivotal, device trial.
    Lancet 2021 Apr 24; 397:1545.
    (https: //doi.
    org/10.
    1016/S0140-6736(21)00475-X) NEJM Journal Watch is published by NEJM Group.
    Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest Progress
    .

    "NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
    .

    Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
    .

    The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
    .

    If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
    cn
    .

    Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.